SCHEMBL4467346

SCHEMBL4467346

C[C@](O)(CC(=O)O)c1cc(F)cc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 1/20 0.43
CHRM1 P11229 1/20 0.43
TBXA2R P21731 1/20 0.43
ADRA1A P35348 1/20 0.43
CYP2C19 P33261 2/20 0.42
HIF1A Q16665 2/20 0.42
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
SLC6A3 Q01959 1/20 0.36
SLC13A5 Q86YT5 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HCAR1 Q9BXC0 1/20 0.35
HDAC6 Q9UBN7 1/20 0.34
KDM4E B2RXH2 1/20 0.33
CHRM3 P20309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4453210 1.00 HMGCR (0.43) HMGCRCHRM1TBXA2RADRA1ACYP2C19
SCHEMBL17582914 0.80 CYP2C19 (0.47) HMGCRCHRM1TBXA2RADRA1ACYP2C19
SCHEMBL17582917 0.80 CYP2C19 (0.47) HMGCRCHRM1TBXA2RADRA1ACYP2C19
SCHEMBL31294629 0.78 RIPK1 (0.41) HMGCRCHRM1TBXA2RADRA1ACYP2C19
SCHEMBL8906633 0.77 CHRM3 (0.36) CES2CES1SLC6A3CHRM3
SCHEMBL31294792 0.76 KCNN4 (0.46) HMGCRCHRM1TBXA2RADRA1ACYP2C19
SCHEMBL11833099 0.76 BCL2L1 (0.46) HMGCRCHRM1TBXA2RADRA1ACYP2C19
SCHEMBL13768567 0.75 RXRA (0.39) RXRARXRBRXRGCES2ALDH1A1
SCHEMBL3941432 0.75 CES2 (0.39) RXRARXRBRXRGTSHRCES2
SCHEMBL3941437 0.75 CES2 (0.39) RXRARXRBRXRGTSHRCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118223-A1 Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives MERCK SHARP & DOHME CORP. 2009-05-07 US disclosed
EP-1915053-A2 NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES Merck & Co., Inc. (US) 2008-04-30 EP disclosed
WO-2007022073-A2 NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES MERCK & CO., INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118223-A1 Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives MTAP, NT5C3B, NSUN2 HMGCR 974/4885CHRM1 1805/4885TBXA2R 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.